A pervasive trend is emerging within pediatric sleep clinics: a significant majority of young patients have, at some point, been administered melatonin, or are currently using it. While melatonin is recognized as a valuable therapeutic tool for sleep disorders in children and is often perceived as safe due to its natural origins, a growing concern centers on its widespread and sometimes unsupervised use. This trend is mirrored by the increasing popularity of magnesium supplements for sleep in children, a topic for which scientific evidence remains limited.
The exact prevalence of melatonin use among children is challenging to quantify precisely. However, a 2022 study published in JAMA indicated a threefold increase in melatonin use among adults between 2005 and 2018, with a concurrent rise in dosage. This surge in adult usage provides a potential indicator of broader societal shifts in sleep aid consumption. Critically, products containing melatonin for children are being aggressively marketed, leading to fears that its accessibility is tempting some parents to use it as a shortcut, bypassing the implementation of fundamental good sleep practices. Anecdotal evidence, such as a father’s review on Amazon quoted in a Wall Street Journal article, highlights this sentiment: "OK, yes, as parents my wife and I should do a better job starting the bedtime routine earlier, turning off the TV earlier, limiting sweets, etc., etc. Well, for whatever reason, this is not our strong suit. This 1 mg light dosage of melatonin is very helpful winding our kids down and getting them ready for bed." This underscores a parental reliance on the supplement when foundational sleep hygiene proves difficult to consistently maintain.
Escalating Usage and Global Trends
While definitive pediatric statistics are elusive, indirect evidence points to a substantial increase in melatonin consumption by children. A New York Times article in May 2020, "Parents Are Relying on Melatonin to Help Their Kids Sleep. Should They?", reported an 87% surge in overall melatonin sales in the year preceding March 2020. A survey conducted by the Times involving 933 parents of children under 18 revealed that over half had given their children melatonin at some point, with one-third reporting a history of sleep difficulties in the past year.
More recent global data paints an even more striking picture. Scandinavia has witnessed an almost 500% increase in melatonin prescriptions. Furthermore, melatonin has become the most common cause of accidental overdose in pediatric emergency rooms and a leading reason for calls to poison control centers in the United States. This escalating reliance on melatonin appears to be a worldwide phenomenon, necessitating a thorough examination of its role in pediatric sleep management.
Understanding Melatonin: Function and Mechanism
Melatonin is a hormone naturally produced by the pineal gland in the brain. It functions as a chronobiotic agent, meaning it regulates the body’s circadian rhythm, or internal clock. At higher doses, it can also exhibit hypnotic effects, inducing sleep. However, it is crucial to distinguish these two roles: while its chronobiotic effect is consistent across individuals, its hypnotic effect is not universally experienced and is dose-dependent.
The natural increase in melatonin levels typically occurs one to three hours before sleep onset, a phenomenon known as the "dim light melatonin onset" (DLMO). This biological signal cues the body for sleep. For children experiencing insomnia, melatonin is often administered after their scheduled bedtime has passed, suggesting their bodies are not yet biologically prepared for sleep. This is one reason why strategies like "bedtime fading" can be effective, as they align with the child’s natural sleep timing. Clinical doses of melatonin, often ranging from 0.5 mg to 10 mg or higher, significantly exceed the physiological amounts naturally secreted by the body.
Effectiveness of Melatonin for Pediatric Sleep Issues: A Nuanced View
The reported benefits of melatonin for children include a reduction in the time it takes to fall asleep and an increase in overall sleep duration. However, similar to many medications used for pediatric sleep induction, the available scientific information is relatively limited. Most studies involve small cohorts and short follow-up periods. A significant contributing factor to this data gap is that melatonin is regulated as a dietary supplement by the U.S. Food and Drug Administration (FDA), rather than as a pharmaceutical. This means it does not benefit from the extensive, long-term safety and efficacy studies typically funded by pharmaceutical companies for prescription drugs.
Comprehensive reviews, such as those provided by the International Pediatric Sleep Association (IPSA), offer valuable insights, including dosing recommendations. These resources distinguish between melatonin for typically developing children and those with specific conditions like autism. The general consensus suggests that melatonin can provide approximately 30 minutes of additional sleep per night, primarily by shortening the sleep onset latency. However, it is not a panacea and its effectiveness can vary.
Chronic Sleep Onset Insomnia in Typically Developing Children
Difficulty falling asleep is a common issue for children, mirroring adult experiences. Chronic insomnia is diagnosed when sleep difficulties occur at least three times per week for three months or more, leading to dissatisfaction with sleep or daytime impairments. A 2023 meta-analysis by Edemann-Callesen, combining data from 419 children, indicated an approximate 30-minute increase in total sleep time, with about 18 minutes attributed to faster sleep onset. Notably, this study found no improvement in daytime functioning and an increase in adverse events in the melatonin treatment group compared to placebo. The 2025 IPSA position paper on melatonin for typically developing children offers critical recommendations for this age group.
Melatonin and Autism Spectrum Disorder (ASD)
Sleep disturbances are particularly prevalent among children with Autism Spectrum Disorder (ASD), manifesting as prolonged sleep onset, reduced nighttime sleep, and frequent awakenings. Some research suggests that children with ASD may have lower natural melatonin levels and reduced daily fluctuations. Consequently, melatonin has been widely used in this population, often demonstrating improvements in sleep onset and duration. Studies have explored both immediate-release and long-acting formulations, typically administered 30-60 minutes before bedtime.
A 2025 meta-analysis by Yang et al. highlighted that the most significant benefits of melatonin in children with ASD were observed in sleep efficiency and total sleep time, rather than solely in sleep latency. The effectiveness of melatonin was found to be greater in older children, and its efficacy could diminish over time. Higher doses appeared to yield more pronounced benefits than lower doses. A 2017 trial investigating a time-released melatonin preparation (PedPRM) at doses of 2-5 mg reported an average increase of 57.5 minutes of sleep compared to a control group, with much of this benefit attributed to a 39-minute reduction in sleep latency. While this specific preparation is available in Europe as Slenyto, its approval by the FDA in the United States is uncertain. The 2024 IPSA recommendations for melatonin use in ASD emphasize a structured approach.
ADHD and Melatonin: Addressing a Common Comorbidity
Attention-Deficit/Hyperactivity Disorder (ADHD) frequently co-occurs with sleep problems, and vice versa. Historical accounts, such as early papers describing the "hyperkinetic behavior syndrome" (now referred to as ADHD), noted parental desperation over nighttime sleep disturbances. Estimates suggest that up to 70% of children with ADHD experience sleep issues, including difficulties falling asleep, altered sleep architecture, and daytime sleepiness.
A 2024 review by Cortese on sleep management in ADHD identified two randomized controlled trials demonstrating positive outcomes. A 2024 systematic review by Larsson reported a 30-minute decrease in sleep latency and improved sleep efficiency, but found no evidence of improvement in quality of life or daytime ADHD symptoms. A small trial did suggest melatonin’s benefit for insomnia in children with ADHD taking stimulants, though this was based on chart review.
Delayed Sleep Phase Syndrome (DSPS) and Melatonin: A Clearer Application
Delayed Sleep Phase Syndrome (DSPS) is a common circadian rhythm disorder among adolescents, characterized by a significant shift in their natural sleep period later than socially mandated schedules, often leading to sleep onset between 1-2 AM or even later. Melatonin plays a more clearly defined role in managing DSPS. Low doses administered several hours before the intended sleep onset, in conjunction with light exposure management, sleep hygiene, and gradual schedule adjustments (chronotherapy), can effectively realign sleep patterns. The underlying issue in DSPS is a delayed DLMO, which melatonin can help to advance. For children with DSPS, a common recommendation involves administering a dose 4-6 hours before the current sleep onset time, gradually advancing it every 4-5 days, using low-dose preparations. This condition arguably presents the most robust evidence for melatonin’s benefit.
Other Pediatric Conditions and Melatonin
Children with various forms of neurodevelopmental delay may experience significant insomnia, and melatonin can be a helpful adjunct. However, concerns exist regarding persistently elevated daytime melatonin levels and subsequent daytime sleepiness in some individuals. A 2023 review by Edemann-Callesen examined melatonin use in a range of conditions, including atopic dermatitis, epilepsy, and neurogenetic disorders, finding an average increase of 19 minutes in total sleep time (primarily due to reduced latency) but no significant improvement in subjective sleep quality or daytime functioning.
For children with blindness, disruptions in the light-dark cycle can impact circadian regulation and lead to sleep disorders. While small trials in adults have shown benefit, data for pediatric populations is very limited. Eczema, characterized by dry, itchy skin, can also be associated with insomnia and non-restorative sleep. Some research suggests that children with eczema may have lower melatonin levels, and preliminary trials indicate potential benefits from melatonin supplementation.
Addressing Concerns: Safety, Side Effects, and Preparations
Despite its widespread use, several concerns warrant attention regarding melatonin in children. These include potential side effects, both known and theoretical, and issues with product quality and labeling.
Theoretical Side Effects: A primary concern is the potential for persistently elevated blood melatonin levels throughout the day, which could lead to daytime sleepiness. However, comprehensive long-term safety data in children remains less robust than for pharmaceuticals. David Kennaway, an Australian physician, has raised concerns about the inadequacy of long-term safety studies in children, noting that melatonin is not registered for pediatric use and is also used in veterinary medicine to alter reproduction in livestock.
Regulatory Oversight and Product Variability: As a dietary supplement, melatonin is subject to less stringent regulatory oversight for safety and efficacy compared to pharmaceuticals. Labeling can be misleading; for instance, a liquid preparation marketed as "1 mg" might actually contain 0.25 mg per dropperful, requiring parents to consult external information for accurate dosing. This lack of clear, standardized labeling can contribute to accidental overdosing or underdosing.
A 2020 study following 80 children for two years on a long-acting melatonin formulation (PedPRM) did not reveal adverse effects on weight, height, BMI, or Tanner staging (a measure of sexual development). This study is considered one of the most reassuring long-term safety assessments, yet the call for more extensive research persists.
Navigating Melatonin Use: Guidance for Parents and Physicians
For parents whose children are already taking melatonin, a measured approach is advised. While significant harm is not definitively established, consulting with a pediatrician to ascertain the necessity of continued use is crucial. If a child has been on melatonin long-term and is sleeping well, a gradual dose reduction or intermittent use, rather than nightly administration, may be considered. Re-emphasizing and reinforcing good sleep hygiene practices, including a consistent bedtime routine and avoiding screen time for at least an hour before bed, is paramount. The IPSA guidelines suggest limiting melatonin use to 3-6 months and periodically attempting to wean the child off the supplement.
Ensuring safe storage of melatonin and appropriate dosing is essential to prevent accidental ingestion and potential interactions with other medications. Parents should also be aware of the increased risk of overdoses, as highlighted in separate safety guidance.
Strategic Considerations for Melatonin Dosing and Administration
When melatonin is deemed appropriate and prescribed by a healthcare professional, careful consideration of timing and dosage is vital. The effectiveness of melatonin can be significantly influenced by when it is administered relative to the child’s natural sleep schedule. A smaller dose given a few hours before bedtime may be more effective than a larger dose administered at bedtime. Generally, a window of 30-60 minutes before bedtime is considered optimal, although earlier administration may be beneficial in some cases.
The 2025 IPSA guidelines provide age-based dosing recommendations, advocating for starting at 0.5 mg and increasing by 0.5 mg weekly until improvement is observed or the maximum dose is reached. Resources such as a melatonin dosing calculator can assist parents and physicians in selecting the safest and most appropriate dose.
Crucially, melatonin should not be viewed as a substitute for robust sleep hygiene practices. It should be integrated into a comprehensive plan that includes a high-quality bedtime routine, controlled light exposure, and an appropriate sleep schedule. When possible, selecting a USP Verified preparation can offer an additional layer of assurance regarding product quality and manufacturing standards.
The Takeaway: When Melatonin Might Be Considered
Decisions regarding medicating children for sleep are often made with considerable deliberation, frequently after non-pharmacological interventions have been exhausted. Treatment options for pediatric insomnia are limited, with few FDA-approved medications available. Melatonin, despite its regulatory status and ongoing safety discussions, is a commonly used tool in pediatric practice, proving beneficial for many children and families. While acknowledging the concerns raised by experts regarding long-term safety, the profound impact of chronic sleep deprivation on children and families cannot be overlooked.
The goal remains to achieve optimal sleep with minimal reliance on medication. For some children, particularly those with autism or developmental delays, medication may be essential for achieving adequate sleep. Melatonin may be a suitable option for a child if:
- Sleep hygiene and behavioral interventions have been consistently implemented and proven insufficient.
- The child has a diagnosed sleep disorder for which melatonin has demonstrated efficacy, such as Delayed Sleep Phase Syndrome.
- The potential benefits of improved sleep outweigh the identified risks, under the guidance of a healthcare professional.
It is also important to consider that sudden sleep disturbances may indicate a sleep regression, for which specific strategies can be employed.
A special acknowledgment is extended to Bob Young R.Ph, for his contributions to the initial development of this article.
